Sep 12, 2009 03:18PM - edited Sep 13, 2009 01:07PM by orange1
I know of a woman with mets (Her2+) who is over 10 years out and doing fine.
Re: Early stagers. Since this drug was just approved for adjuvant treatment in 2006, no one really knows the long term results. I think oncs just assume that we will follow the course depending on our hormone receptor status - similar to our Her2- sisters. So they tell the HR- that after a few years they are clear, and the assumption is that HR+ always have some risk.
Now this is the good part for HR+ Her2+ early stagers, I have found a small study that looks at Her2+ HR+ for many years out (I think 15, I'll have to check when I get back to the office). Anyway, in this small study Her2+, HR+ stopped recurring after about 5 or 6 years. That is totally stopped recurring, not one (but like I said a very small study). These women were treated with tamoxifen only - no chemo no Herceptin.